Improving the effectiveness of treatment of hypertensive encephalopathy with the drug Mexidol

Authors:
E.V. BOLOTOVA ¹ , T.Yu. LUSHPAY ² , I.V. KOVRIGINA ²

¹ Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation, Krasnodar, Russia;
² State Budgetary Healthcare Institution “Research Institute — Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky” of the Ministry of Health of Krasnodar Krai, Krasnodar, Russia

Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 4, 2018

Abstract:
Objective of the study. To evaluate the efficacy and tolerability of Mexidol as a cognitive impairment corrector in patients with arterial hypertension and clinical manifestations of chronic cerebral circulatory insufficiency. Material and methods. Forty-two patients with clinical manifestations of chronic cerebral ischemia (CCI) and cognitive impairment were examined. Patients of the 1st group (n=21) received traditional antihypertensive therapy, patients of the 2nd group (n=21) — antihypertensive drugs and Mexidol. To assess the neuropsychological status, the MMSE, MoCA scales, and the clock drawing test were used. To monitor adherence to therapy, a questionnaire was conducted using the Morisky-Green test. Results and conclusion. After a course of treatment with Mexidol, the number of patients with no complaints increased 3-fold, regression of headache was noted in 90% of patients, improved memory, concentration, disappearance of anxiety - in 50, 55, 67%, respectively. Patients in Group 2 (Mexidol) showed more significant changes in the clock drawing test compared to Group 1 (0.95 and 0.54 points, respectively; p < 0.02). Significant positive dynamics were revealed on the MMSE and MoCA scales, indicating the drug's effective effect on neurodynamic cognitive symptoms and well-being in patients with hypertensive-related CCI. Mexidol is recommended for use in this group of patients as part of complex therapy for the underlying disease. Key words: Mexidol, cognitive impairment, adherence.